|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Atypical chronic myeloid leukemia (aCML) is a BCR-ABL1 negative myelodysplastic (MDS)/myeloproliferative (MPN) neoplasm with poor overall survival.
|
30078497 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We conclude that BCR-ABL1 kinase-dependent and -independent mechanisms convert p27 from a nuclear tumor suppressor to a cytoplasmic oncogene.
|
25293778 |
2014 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We performed integrated genome-wide chromatin and expression analyses and identified Ikaros target genes in mouse and human BCR-ABL1<sup>+</sup> pre-B ALL, revealing novel conserved gene pathways associated with Ikaros tumor suppressor function.
|
28190001 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Studies involving BCR transgenic mice indicated that B cells inhibit anti-tumor T cell responses through antigen non-specific mechanisms.
|
24293009 |
2013 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
BCR-ABL1-like B-lymphoblastic leukemia/lymphoma (BCR-ABL1-like B-ALL), also known as Philadelphia-like (Ph-like) ALL, is a neoplasm of B-lineage lymphoblasts characterized by a pattern of gene expression similar to that of B-ALL with the BCR-ABL1 translocation but lacking the BCR-ABL1 fusion protein.
|
29696694 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy.
|
25941032 |
2015 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Among these cancers are chronic neutrophilic leukemia (CNL) and atypical (BCR-ABL1-negative) chronic myeloid leukemia (CML), both of which are diagnosed on the basis of neoplastic expansion of granulocytic cells and exclusion of genetic drivers that are known to occur in other myeloproliferative neoplasms and myeloproliferative-myelodysplastic overlap neoplasms.
|
23656643 |
2013 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Given the distinct clinical and pathological characteristics, we believe that hematological neoplasms harboring BCR-JAK2 should be included as an additional distinct entity to the current WHO category of "myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR", and testing for a JAK2 fusion should be pursued in neoplasms with a karyotypic 9p24 abnormality.
|
27134074 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The degree of tumor load reduction after therapy is an important prognostic factor for patients with CML.
|
10865964 |
2000 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In this respect, the rather clear description of CML in cytogenetic, clinical, and laboratory terms, the relatively long chronic phase of the disease, and the association of the blastic phase with nonrandom chromosome changes (at least in the initial phases of the disease) make Ph-positive CML an excellent candidate for a model for the study of molecular events in human neoplasia.
|
3004697 |
1986 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Cytogenetic and molecular genetic analysis are important in the diagnosis of CML and are becoming increasingly important in the diagnosis of chronic LPDs and other haematological neoplasms.
|
7665691 |
1995 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
It is important to recognize that neoplasms carrying the t(8;22)/BCR-FGFR1, although rare, can commonly with B lymphoblastic leukemia at the initial diagnosis, which could distract one from recognizing a possible underlying 8p11 myeloproliferative syndrome.
|
28551329 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Atypical chronic myeloid leukemia (aCML) and chronic neutrophilic leukemia (CNL) are rare BCR-ABL1 fusion gene-negative myeloid neoplasms with a predominance of neutrophils.
|
30458320 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Thus, wild-type IKAROS restrains stemness properties and has tumor suppressor activity in BCR-ABL1-initiated leukemia.
|
24791856 |
2015 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
|
25260694 |
2015 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
RT-PCR analysis, performed on total RNA isolated from both neoplastic and normal tissue samples, revealed an ALPHA-TFEB chimeric transcript in the tumor sample; sequencing of the RT-PCR product defined a novel TFEB gene breakpoint cluster region, broader than the one reported thus far.
|
17285572 |
2007 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In this particular review we discuss the oncogenes and tumor suppressors comprising the regulatory network upstream and downstream of BCR-ABL1 and dismantle how derailed BCR-ABL1 signaling provides cell a selective growth advantage.
|
23575065 |
2013 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The possibility of tumor‑derived exosomes enrichment was confirmed, and for the first time, to the best of our knowledge, the detection of the BCR‑ABL1 transcript highlighted the presence of active leukemic cells in patients with CP‑CML.
|
31638195 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Finally, when administered intraperitoneally, ART inhibited p38, ERK, STAT5, and CREB activation in tumor tissues and the growth of human CML xenograft tumors in mice without exhibiting any significant adverse effects.
|
25738364 |
2015 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Dasatinib, a dual Src/Abl kinase inhibitor approved for the treatment of CML, is under investigation as monotherapy for tumors with abnormal Src signaling, such as melanoma.
|
24281418 |
2014 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We investigated adhesion pathways that contribute to engraftment of breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1)-induced chronic myelogenous leukemia (CML)-like myeloproliferative neoplasia in a mouse retroviral transduction/transplantation model.
|
24394666 |
2014 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Several data from immunoglobulin gene (IG) analysis have provided hints regarding the cell of origin and the ongoing selective interactions of the tumour BCR with environmental stimuli.
|
21674564 |
2011 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We will suggest control experiments and outline further methods that are required to allow for assessment of disease development upon tumor suppressor knockout in CML.
|
27581141 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
These results demonstrate that targeting both bcr3/abl2 and VEGF can result in an additive tumor-suppressive action and may represent an excellent strategy to augment the efficacy of chemotherapy in CML.
|
16034468 |
2005 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In K562 leukemia cells, overexpression of miR-30a reduced ABL1 and BCR-ABL1 protein expression, decreased proliferation, and arrested cell cycle progression between G1 and S. These findings strongly suggest that miR-30a acts as a tumor suppressor by downregulating ABL1 and BCR-ABL1 expression.
|
23287430 |
2013 |